TGFβ1 R25P 单核苷酸多态性与直肠癌新辅助放化疗急性毒性相关
在165例2006至2012年接受直肠癌放化疗的独立队列中,验证单核苷酸多态性与毒性的关联。TGFβ1 R25P 多态性与≥3级毒性显著相关(OR 3.47,P=.04),在完成肠道问题量表的患者中与≥4级毒性相关(OR 5.61,P=.02),多变量模型校正后仍显著(校正OR 1.83,P=.02)。
要点
- TGFβ1 R25P 与放化疗期间≥3级毒性显著相关(OR 3.47,P=.04)。
- 完成肠道问题量表者中,TGFβ1 R25P 与≥4级毒性相关(OR 5.61,P=.02)。
- 所有14例≥3级毒性患者均携带 XRCC1 R399Q 或 TGFβ1 R25P 多态性。
核心结论
- 在独立队列中验证了 TGFβ1 R25P 单核苷酸多态性与直肠癌放化疗期间急性毒性的相关性,且基于临床医生和患者报告的毒性均一致。
研究设计与样本
- 研究纳入2006至2012年接受放化疗的165例直肠癌患者,从直肠切除标本正常组织提取DNA筛查3个SNP:XRCC1 R399Q、XPD K751Q 和 TGFβ1 R25P。
- 毒性按常见不良事件评价标准3.0版前瞻性记录并从病历调取,其中52例患者每周使用7项肠道问题量表记录胃肠道症状。
- 采用单变量和多变量逻辑回归模型分析。
主要发现
- 中位放疗剂量为50.4 Gy,所有患者均接受同步化疗。
- 14例患者(8%)在放化疗期间发生≥3级毒性,全部14例均携带 XRCC1 R399Q 或 TGFβ1 R25P 多态性。
- TGFβ1 R25P 多态性与≥3级毒性显著相关(OR 3.47,P=.04)。
- 在完成肠道问题量表的患者中,TGFβ1 R25P 与≥4级毒性相关(OR 5.61,P=.02)。
- 校正种族、年龄和性别后,TGFβ1 R25P 与≥4级毒性的关联在多变量模型中仍显著(校正OR 1.83,P=.02)。
关键数值与推荐
- TGFβ1 R25P 与≥3级毒性:OR 3.47,P=.04。
- TGFβ1 R25P 与≥4级毒性(完成肠道问题量表者):OR 5.61,P=.02。
- 多变量校正后 TGFβ1 R25P 与≥4级毒性:校正OR 1.83,P=.02。
临床怎么用
- TGFβ1 R25P 可作为局部晚期直肠癌新辅助治疗急性毒性生物标志物的候选,供设计前瞻性试验验证其效用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To validate the finding of an association between single nucleotide polymorphisms (SNPs) and toxicity during chemoradiotherapy (CRT) in rectal cancer patients, in an independent population. METHODS AND MATERIALS: The cohort consisted of 165 patients who received CRT for rectal cancer from 2006 to 2012. Prospectively recorded toxicity information, graded according to the Common Terminology Criteria for Adverse Events version 3.0, was retrieved from the medical record. Additionally, a subset of 52 patients recorded their gastrointestinal symptoms weekly during CRT, using the 7-item Bowel Problems Scale. Deoxyribonucleic acid was extracted from normal tissue in the proctectomy specimens and screened for 3 SNPs: XRCC1 R399Q, XPD K751Q, and TGFβ1 R25P. Univariable and multivariable logistic regression models were constructed. RESULTS: The median radiation dose was 50.4 Gy, and all patients received concurrent chemotherapy. Toxicities measured by the Common Terminology Criteria for Adverse Events were closely associated with patient-reported outcomes for the patients who completed the 7-item Bowel Problems Scale. Grade ≥3 toxicity occurred during CRT in 14 patients (8%). All 14 patients had either XRCC1 R399Q or TGFβ1 R25P polymorphisms. The TGFβ1 R25P polymorphism was significantly associated with grade ≥3 toxicity (odds ratio [OR] 3.47, P=.04) and, in patients who completed the Bowel Problems Scale, with grade ≥4 toxicity (OR 5.61, P=.02). The latter finding persisted in a multivariable logistic regression model controlling for ethnicity, age, and sex (adjusted OR 1.83, P=.02). CONCLUSIONS: We have validated the correlation between the TGFβ1 R25P SNP and acute toxicity during CRT in an independent cohort using both clinician- and patient-reported toxicity. The information from our study could be used as a basis to formulate a prospective trial testing the utility of this SNP as a biomarker of acute toxicity during neoadjuvant treatment in locally advanced rectal cancer.
引用
- Smith JJ, Wasserman I, Milgrom SA, et al. Single Nucleotide Polymorphism TGFβ1 R25P Correlates with Acute Toxicity during Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients. Int J Radiat Oncol Biol Phys. 2016. PMID: 28333014. doi:10.1016/j.ijrobp.2016.12.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。